君合盟生物：重组A型肉毒毒素治疗原发性腋窝多汗症获临床批件

Core Viewpoint - Junhe Alliance Biopharmaceuticals has made significant progress in the development and clinical application of recombinant type A botulinum toxin, particularly for the treatment of primary axillary hyperhidrosis, with the IND application approved by the National Medical Products Administration [2][3] Group 1: Company Overview - Junhe Alliance Biopharmaceuticals is an innovative company focused on synthetic biology technology, aiming to advance recombinant protein drugs in endocrine, neurological treatments, and next-generation biomedical materials [2] - The company’s product pipeline includes recombinant A-type botulinum toxin, human growth hormone injection, long-acting growth hormone, single-layer artificial dermis, double-layer artificial dermis, and cartilage repair scaffolds [2] Group 2: Product Development - The recombinant A-type botulinum toxin is developed using genetic engineering, protein engineering, and synthetic biology, overcoming key technical barriers in recombinant expression and formulation processes [3] - This product demonstrates significant advantages in purity, activity, and safety, positioning it as a potential upgrade to traditional botulinum toxin products [3] Group 3: Market Impact - Junhe Alliance Biopharmaceuticals is one of the first companies globally to master the core technology of recombinant A-type botulinum toxin, expanding its research into various treatment areas including adult upper limb spasticity, adult lower limb spasticity, primary axillary hyperhidrosis, and eyelid spasm [3] - The company aims to reshape the competitive landscape of the botulinum toxin market, accelerating the replacement of traditional and overseas products with a new generation of safer, more controllable, and more efficient products [3]